Study Supports CyberKnife's Clinical Flexibility, Expanding Physicians
Options for the Treatment of Prostate Cancer
SUNNYVALE, Calif., April 8, 2008 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that a study published in the April 1 issue of the International Journal of Radiation Oncology*Biology*Physics -- also known as the Red Journal -- demonstrates that the CyberKnife(R) Robotic Radiosurgery System can serve as a non-invasive means for delivering high dose rate (HDR) brachytherapy dosing. The study supports the CyberKnife System's clinical flexibility in treating prostate cancer and expands the non-invasive options available to clinicians and patients.
HDR brachytherapy has been shown to be an extremely effective approach for treating prostate cancer, with substantial clinical evidence supporting its usage. Nevertheless, the required insertion of multiple catheters into the prostate, where they remain for the duration of the procedure (typically 1-3 days), makes it an invasive procedure.
This study demonstrates the CyberKnife System's ability to non-invasively deliver complex HDR-like radiation dose sculpting to the prostate, without the need for hospitalization or anesthesia, maximizing patient comfort and convenience. Early clinical outcomes of the study show a rapid reduction in prostate specific antigen (PSA) levels with minimal short-term side effects.
"HDR brachytherapy is an effective, accepted treatment for prostate
cancer, but adoption has been limited because it is a difficult procedure
for clinicians to deliver and for patients to undergo," said Donald B.
Fuller, M.D., radiation oncologist, CyberKnife
|SOURCE Accuray Incorporated|
Copyright©2008 PR Newswire.
All rights reserved